Anti-transforming growth factor beta as a treatment for laryngotracheal stenosis in a canine model

Laryngoscope

Volumn 118, Issue 3, 2008, Pages 546-551

  Simpson, C Blake ^a   White, Stephen ^a   McGuff, H Stan ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

Fibrogenic peptide; Growth factors; Subglottic stenosis; Tracheal stenosis; Transforming growth factor beta

Indexed keywords

SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUTERIZATION; CONTROLLED STUDY; DOG; LARYNGOTRACHEAL STENOSIS; LARYNX STENOSIS; LUNG INJURY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBGLOTTIC STENOSIS; SURVIVAL TIME; TRACHEA STENOSIS; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; DOGS; LARYNGOSTENOSIS; TRACHEAL STENOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 42449106946     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31815daf6e     Document Type: Article

References (26)

1. Papsidero MJ, Pashley NRT. Acquired stenosis of the upper airway in neonates: an increasing problem. Ann Otol Rhinol Laryngol 1980;89:512-514.
2. Ratner I, Whitfield J. Acquired subglottic stenosis in the very low-birth-weight infant. Am J Dis Child 1983;137:40-43.
3. Sadeghi HM, Seitz B, Hayashi S, et al. In vitro effects of Mitmycin-C on human keratocytes. J Refact Surg 1998;14:534-540.
4. Ferguson MK. The effect of antineoplastic agents on wound healing. Surg Gynecol Obstet 1982;154:421-429.
5. Scioscia KA, April MM, Miller F, Gruber BL. Growth factors in subglottic stenosis. Ann Otol Rhinol Laryngol 1996;105:936-943.
6. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor B. Lancet 1992;339:213-214.
7. Islam M, Burke JF, McGowan TA, et al. Effect of antitransforming growth factor-B antibodies in cyclosporine-induced renal dysfunction. Kidney International 2001;59:498-506.
8. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-B ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney International 2000;58:2301-2313.
9. Thom SB, Myers JS, Rapuano CJ, et al. Effect of topical anti-transforming growth factor-B on corneal stromal haze after photorefractive keratectomy in rabbits. J Cataract Refract Surg 1997;23:1324-1330.
10. Jester JV, Barry-Lane PA, Petroll WM. Inhibition of corneal fibrosis by topical application of blocking antibodies to TGFB in the rabbit. Cornea 1997;162:177-187.
11. Dillard DG, Gal AA, Roman-Rodriguez J, et al. Transforming growth factor and neutralizing antibodies in subglottic stenosis. Ann Otol Rhinol Laryngol 2001;110:393-400.
12. Eliashar R, Eliachar I, Gramlich T, Esclamado R, Strome M. Improved canine model for laryngotracheal stenosis. Otol Head Neck Surgery 2000;122:84-90.
13. Eliashar R, Eliachar I, Esclamado R. Can topical Mitomycin prevent laryngotracheal stenosis? Laryngoscope 1999;109:1594-1600.
14. Huber, M. Henderson RA, Finn-Bodner S, et al. Assessment of current techniques for determining tracheal luminal stenosis in dogs. AJVR 1997;58:1051-1054.
15. Ribeiro FD, Guaraldo L, Borges JD, et al. Clinical and histological healing of surgical wounds treated with Mitomycin C. Laryngoscope 2004;114:148-152.
16. Correa AJ, Reinisch L, Sanders DL, et al. Inhibition of subglottic stenosis with mitomycin C in the canine model. Ann Otol Rhinol Laryngol 1999;108:1053-1060.
17. Pimentel E. Handbook of Growth Factors, Volume 1: General Basic Aspects. Boca Raton FL: CRC Press; 1994.
18. Whitby DJ, Ferguson MW. The extracellular matrix of lip wounds in fetal, neonatal, and adult mice. Development 1991;112:651-668.
19. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor. Proc Natl Acad Sci USA 1981;78:5339.
20. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type B: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci 1986;83:4176.
21. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;107:1137-1157.
22. Brahmatewari J, Serafini A, Serralta V, Merta PM, Eaglstein WH. The effects of topical transforming growth factor-B2 and anti-transforming growth factor B-2,3 on scarring in pigs. J Cut Med Surg 2000;4:126-131.
23. Karagiannidis C, Velehorschi Q, Obertrifter B, Macha HN, Linder A, Freitag L. High-level expression of matrix-associated transforming growth factor-beta1 in benign airway stenosis. Chest 2006;129:1298-1304.
24. Thompson JE, Vaughan TJ, Williams AJ, et al. A fully human antibody neutralising biologically active human TGFB2 for use in therapy. J Immunol Methods 1999;227:17-29.
25. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor B2 monocloncal antibody - a new modulator of wound healing in trabeculectomy. Ophthalmology 2002;109:427-431.
26. Lu L, Saulis AS, Liu WR, et al. The temporal effects of anti-TGF-beta1,2 and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 2005;201:391-397.